Oblique Therapeutics Enters Into Research Collaboration Agreement With Eli Lilly To Apply AbiProt To Generate Antibodies To High-Value Targets
Portfolio Pulse from Benzinga Newsdesk
Oblique Therapeutics has entered a research collaboration agreement with Eli Lilly to use AbiProt technology for generating antibodies targeting high-value targets.
August 22, 2024 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly has partnered with Oblique Therapeutics to utilize AbiProt technology for developing antibodies against high-value targets, potentially enhancing its product pipeline.
The partnership with Oblique Therapeutics to use AbiProt technology could lead to the development of new antibodies, enhancing Eli Lilly's product offerings and potentially boosting its market position.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80